• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Hyperfine Inc.

    4/7/25 4:06:35 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $HYPR alert in real time by email
    DEFA14A 1 d840466ddefa14a.htm DEFA14A DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Under §240.14a-12

    Hyperfine, Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     


                    
                         
       

     

    Your Vote Counts!

          

        

     

     

    HYPERFINE, INC.

     

    2025 Annual Meeting

     Vote by May 18, 2025  

    11:59 PM ET

         
       

     

    HYPERFINE, INC.

    351 NEW WHITFIELD ST.

    GUILFORD, CONNECTICUT 06437, UNITED STATES

     

    LOGO  

         

       
       
       
       
         

     

         
     
     
         
     
         

    V68282-P29251

                  
                 

    You invested in HYPERFINE, INC. and it’s time to vote!

    You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held virtually via live audio webcast on May 19, 2025.

    Get informed before you vote

    View the Notice, Proxy Statement, Form of Proxy and Annual Report to Stockholders online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 5, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

     

    LOGO

    *Please check the meeting materials for any special requirements for meeting attendance.

     


    Vote at www.ProxyVote.com

     

     

    THIS IS NOT A VOTABLE BALLOT

    This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters.

     

     Voting Items

     

      

    Board

    Recommends

     

     

     1.   Election of Directors

      
     

         Nominees:

      

     1a.   R. Scott Huennekens

       LOGO  For

     1b.  Maria Sainz

       LOGO  For

     1c.   John Dahldorf

       LOGO  For

     1d.  Ruth Fattori

       LOGO  For

     1e.   Jonathan M. Rothberg, Ph.D.

       LOGO  For

     1f.   Daniel J. Wolterman

       LOGO  For

     2.   To ratify the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.

       LOGO  For

     

     

      

     

     

    Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.

     

    V68283-P29251

    Get the next $HYPR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HYPR

    DatePrice TargetRatingAnalyst
    8/11/2022$8.00 → $2.40Overweight → Equal Weight
    Wells Fargo
    5/31/2022$7.00Outperform
    Evercore ISI
    4/14/2022$8.00Overweight
    Wells Fargo
    More analyst ratings

    $HYPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Teisseyre Thomas sold $1,531 worth of shares (1,151 units at $1.33), decreasing direct ownership by 0.30% to 381,062 units (SEC Form 4)

    4 - Hyperfine, Inc. (0001833769) (Issuer)

    8/18/25 4:10:40 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Wolterman Dan

    4 - Hyperfine, Inc. (0001833769) (Issuer)

    6/6/25 4:01:04 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CFO and CAO Hale Brett was granted 300,000 shares (SEC Form 4)

    4 - Hyperfine, Inc. (0001833769) (Issuer)

    5/20/25 5:26:31 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HYPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Hyperfine downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Hyperfine from Overweight to Equal Weight and set a new price target of $2.40 from $8.00 previously

    8/11/22 6:32:27 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Evercore ISI initiated coverage on Hyperfine with a new price target

    Evercore ISI initiated coverage of Hyperfine with a rating of Outperform and set a new price target of $7.00

    5/31/22 7:16:51 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Wells Fargo initiated coverage on Hyperfine with a new price target

    Wells Fargo initiated coverage of Hyperfine with a rating of Overweight and set a new price target of $8.00

    4/14/22 7:32:25 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HYPR
    Leadership Updates

    Live Leadership Updates

    View All

    QuidelOrtho Announces Appointment of Two Independent Directors to its Board

    Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

    12/10/24 7:00:00 AM ET
    $CTLT
    $HYPR
    $NVST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    Hyperfine Announces Strategic Leadership Additions to Drive Growth in Key Business Verticals

    Two new executive roles position Hyperfine to drive the adoption of the Swoop® system in hospital settings and expand into the office setting, laying the foundation for significant growth in 2025 and beyond. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the appointment of Chi Nguyen as Vice President of Office Strategy and Partnerships and Rafael Donnay as Vice President of Hospital Strategy and Health Economics to provide leadership in key growth areas. These strategic leadership appointments bolster t

    12/3/24 9:00:00 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hyperfine, Inc. Continues Global Market Expansion by Entering Into a Distribution Partnership with Radiosurgery Global, Ltd. to Bring the Swoop® System to India

    Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced it has entered into a distribution agreement with Radiosurgery Global, Ltd. to develop the market in India. The distribution agreement also includes the countries of Malaysia, Indonesia, and Singapore through future expansion, offering Hyperfine, Inc. a significantly increased presence in Asia. The clinical value of the Swoop®

    5/28/24 9:00:00 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HYPR
    Financials

    Live finance-specific insights

    View All

    Hyperfine, Inc. Reports Second Quarter 2025 Financial Results

    GUILFORD, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced second quarter 2025 financial results and provided a business update. "In the second quarter, we executed across our key growth drivers. We received FDA clearances for our latest software, Optive AITM, and for the next generation Swoop® system powered by Optive AITM software, which represent a key inflection point in our technology. We also completed our pilot neurology office program. We believe these criti

    8/13/25 4:05:00 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hyperfine, Inc. to Announce Second Quarter 2025 Financial Results on August 13, 2025

    Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that it will report financial results for the second quarter 2025 on Wednesday, August 13, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. About the Swoo

    7/30/25 4:05:00 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hyperfine, Inc. to Announce First Quarter 2025 Financial Results on May 13, 2025

    Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. About the Swo

    4/29/25 4:28:00 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HYPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Hyperfine Inc.

    SC 13G - Hyperfine, Inc. (0001833769) (Subject)

    2/13/24 5:06:19 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Hyperfine Inc. (Amendment)

    SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)

    2/14/23 4:07:09 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Hyperfine Inc. (Amendment)

    SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)

    12/20/22 4:22:37 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HYPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hyperfine, Inc. Reports Second Quarter 2025 Financial Results

    GUILFORD, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced second quarter 2025 financial results and provided a business update. "In the second quarter, we executed across our key growth drivers. We received FDA clearances for our latest software, Optive AITM, and for the next generation Swoop® system powered by Optive AITM software, which represent a key inflection point in our technology. We also completed our pilot neurology office program. We believe these criti

    8/13/25 4:05:00 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hyperfine Achieves Clinical Milestone Ahead of Plan With 100th Patient Enrolled in Neurology Office Study Using the Next-Generation Swoop® System

    NEURO PMR study evaluates the clinical utility and patient experience of AI-powered portable MRI in an outpatient setting Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system— today announced the successful enrollment of 100 patients in its NEURO PMR (Neurological Evaluation in the Office with Portable MRI) study just 16 weeks after the study initiation, announced on April 15, 2025. This milestone reflects strong clinician enthusiasm for accessible, point-of-care brain imaging and supports Hyperfine's market expansion into outpatient neurology o

    8/4/25 8:15:00 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hyperfine Announces First Patients Enrolled in PRIME Study Aimed at Accelerating Adoption of AI-Powered Portable MRI in Emergency Departments

    The real-world study will assess the clinical and operational impact of portable MRI across diverse patient types in ED settings. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance imaging (MRI) system for the brain—the Swoop® system—today announced the enrollment of the first patients in the PRIME (Portable Rapid Imaging for Medical Emergencies) study. This study aims to evaluate the potential of AI-powered portable MRI technology to transform triage in the emergency department (ED) setting. The PRIME study at Yale School of Medicine builds on the ACTION PMR study

    7/31/25 8:15:00 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HYPR
    SEC Filings

    View All

    SEC Form 10-Q filed by Hyperfine Inc.

    10-Q - Hyperfine, Inc. (0001833769) (Filer)

    8/13/25 4:15:45 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hyperfine Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Hyperfine, Inc. (0001833769) (Filer)

    8/13/25 4:10:27 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hyperfine Inc. filed SEC Form 8-K: Other Events

    8-K - Hyperfine, Inc. (0001833769) (Filer)

    8/6/25 4:01:27 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care